BioAtla Inc. (BCAB), a clinical-stage biopharmaceutical company, has a couple of near-term catalysts to watch.
The company is developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancers. It has 4 clinical-stage drug candidates - BA3011, BA3021, BA3071, and BA3182.
BA3011 is a conditionally active biologic (CAB) anti-AXL antibody-drug conjugate that is under a phase II potentially registrational study in undifferentiated pleomorphic sarcoma.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.